Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells
Uta Kossatz, … , Jeffrey D. Singer, Nisar P. Malek
Uta Kossatz, … , Jeffrey D. Singer, Nisar P. Malek
Published October 11, 2010
Citation Information: J Clin Invest. 2010;120(11):3820-3833. https://doi.org/10.1172/JCI41959.
View: Text | PDF
Research Article Oncology

The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells

  • Text
  • PDF
Abstract

Cyclin E is often overexpressed in cancer tissue, leading to genetic instability and aneuploidy. Cullin 3 (Cul3) is a component of the BTB-Cul3-Rbx1 (BCR) ubiquitin ligase that is involved in the turnover of cyclin E. Here we show that liver-specific ablation of Cul3 in mice results in the persistence and massive expansion of hepatic progenitor cells. Upon induction of differentiation, Cul3-deficient progenitor cells underwent substantial DNA damage in vivo and in vitro, thereby triggering the activation of a cellular senescence response that selectively blocked the expansion of the differentiated offspring. Positive selection of undifferentiated progenitor cells required the expression of the tumor suppressor protein p53. Simultaneous loss of Cul3 and p53 in hepatic progenitors turned these cells into highly malignant tumor-initiating cells that formed largely undifferentiated tumors in nude mice. In addition, loss of Cul3 and p53 led to the formation of primary hepatocellular carcinomas. Importantly, loss of Cul3 expression was also detected in a large series of human liver cancers and correlated directly with tumor de-differentiation. The expression of Cul3 during hepatic differentiation therefore safeguards against the formation of progenitor cells that carry a great potential for transformation into tumor-initiating cells.

Authors

Uta Kossatz, Kai Breuhahn, Benita Wolf, Matthias Hardtke-Wolenski, Ludwig Wilkens, Doris Steinemann, Stephan Singer, Felicitas Brass, Stefan Kubicka, Brigitte Schlegelberger, Peter Schirmacher, Michael P. Manns, Jeffrey D. Singer, Nisar P. Malek

×

Figure 6

Loss of p53 in Cul3-knockout progenitor cells leads to generation of tumor-initiating cells in vivo.

Options: View larger image (or click on image) Download as PowerPoint
Loss of p53 in Cul3-knockout progenitor cells leads to generation of tum...
(A) Transplantation of Cul3-knockout and Cul3/p53-knockout progenitor cells into nude mice. Shown is the average of 6 tumors from 3 mice after injection of 1 × 106 cells. P values for the increase in tumor size were calculated using the t test and are as follows: d 31/d 41, P = 0.0034; d 31/d 39, P = 0.744; d 39/d 48, P = 0.0022. (B) H&E staining of tumors derived from nude mice. CK14 and CD34 (bottom left panels) immunofluorescence staining to identify cells with stem cell characteristics. The bottom right panels show DAPI staining. Scale bars: 50 μm. (C) Primary hepatocellular tumors arise in Cul3/p53 double-knockout livers (area indicated by arrow), while no tumors can be found in Cul3-knockout livers. For comparison, WT livers are shown. Scale bars: 200 μm. (D) Analysis of Cul3 and cyclin E protein levels in normal human liver tissue (nt) and hepatocellular carcinoma (HCC-G3) by immunohistochemistry. Original magnification, ×40. (E) HCC tissues show a strong downregulation of Cul3 and induction of cyclin E expression as measured by immunohistochemistry in normal human liver, dysplastic nodes, and hepatocellular cancers. De-differentiation of tumors correlated with the decrease in Cul3 protein (r = –0.375; P = 0.0001). Expression ranges from 0 (no expression) to 3 (strong expression). Increase in cyclin E protein levels and decrease in Cul3 protein levels correlated significantly upon de-differentiation of tumors (r = –0.476; P = 0.046).

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts